USFDA approves Zydus Lifesciences’ generic version of a cholesterol-lowering medication.
Zydus Lifesciences has received approval from the US Food and Drug Administration (USFDA) for its generic version of a cholesterol-lowering drug. The company announced that it has received tentative approval for its generic version of Pitavastatin Calcium Tablets, which is used to treat high cholesterol and reduce the risk of cardiovascular disease.
Pitavastatin Calcium Tablets are a generic version of the brand-name drug Livalo, which is manufactured by Kowa Pharmaceuticals America, Inc. and marketed by Eisai Inc. The drug works by inhibiting the production of cholesterol in the liver, which helps to lower the levels of “bad” cholesterol in the blood.
The USFDA approval is a significant milestone for Zydus Lifesciences, as it expands the company’s portfolio of generic medicines in the US market. The company’s generic version of Pitavastatin Calcium Tablets will be available in various strengths, including 1mg, 2mg, and 4mg tablets.
Zydus Lifesciences has a strong presence in the US generic market, with a portfolio of over 200 generic products. The company has been expanding its US operations in recent years, with a focus on developing and marketing a range of generic and specialty medicines.
The approval of the generic version of Pitavastatin Calcium Tablets is expected to increase access to this important medicine for patients in the US who are struggling with high cholesterol. High cholesterol is a major risk factor for cardiovascular disease, which is one of the leading causes of death and disability in the US.
The USFDA approval also highlights the company’s commitment to providing high-quality, affordable medicines to patients around the world. Zydus Lifesciences has a strong track record of developing and marketing generic medicines that meet the high standards of quality and efficacy set by regulatory authorities such as the USFDA.
Overall, the approval of the generic version of Pitavastatin Calcium Tablets is a significant achievement for Zydus Lifesciences, and it reflects the company’s ongoing efforts to expand its presence in the US generic market. As the company continues to develop and market new generic and specialty medicines, it is likely to remain a major player in the global pharmaceutical industry.
In conclusion, Zydus Lifesciences has received USFDA approval for its generic version of Pitavastatin Calcium Tablets, which is used to treat high cholesterol and reduce the risk of cardiovascular disease. This approval expands the company’s portfolio of generic medicines in the US market and reflects its commitment to providing high-quality, affordable medicines to patients around the world.
Nabil Bank partners with Apollo Information Centre to provide customers with a 10% discount – Insurance Khabar
Nabil Bank Limited, a leading private sector bank in Nepal, has signed a Memorandum of Understanding (MoU) with Apollo Information Centre, the official representative organization of Apollo Hospitals in India. The agreement aims to provide special discounts and facilitation to Nabil Bank’s customers who undergo medical treatment at Apollo Hospital in India.
Under the MoU, Nabil Bank customers will receive up to 10% special discount and personal counseling services while undergoing treatment at Apollo Hospital. The bank’s customers, employees, and shareholders will be eligible for these discounts and services, which can be availed by making payments through debit and credit cards, Nabil QR, Nabil Smart Mobile App, or bank transfer.
The MoU was signed by Krishna Prasad Subedi, Chief Marketing Officer of Nabil Bank, and Sushil Kumar Chapagain, Managing Director (Law) of Apollo Information Centre. Subedi stated that the agreement will make it easier for the bank’s customers to access quality health services at an affordable cost. He noted that a significant number of Nepalis travel to India for medical treatment, and this agreement will facilitate their access to world-class health services.
The MoU will be in force for two years, and customers can visit the bank’s website for more information about the special discounts and services being offered. Nabil Bank has a strong commitment to contributing to the development of the country and society, and this collaboration is expected to benefit Nepali patients seeking specialized health services in India.
Apollo Information Centre, with its office in Kathmandu, has been providing services with skilled health workers and experienced entrepreneurs. Nabil Bank, with its extensive network of 268 branches and 320 ATM machines across the country, has been serving over 2.4 million customers and has played a leading role in introducing innovative services in the Nepali banking sector. This partnership is expected to further enhance the bank’s reputation as a responsible and customer-centric institution.
Jackie Shroff Lends Support to Fortis’ ‘Red Run to End Thalassemia’ Awareness Campaign!
Bollywood actor Jackie Shroff has once again taken on the role of Brand Ambassador for a nationwide movement to eliminate Thalassemia from India by 2035. The initiative, #RedRuntoEndThalassemia, was launched by Fortis Memorial Research Institute, Gurugram, and aims to raise awareness about the genetic blood disorder. Thalassemia is a preventable condition that affects over 10,000 to 15,000 children born in India every year.
The event, which saw the participation of over 2,000 individuals, covered a distance of 5 kilometers to support the cause. Jackie Shroff addressed the gathering, emphasizing the importance of ending Thalassemia and highlighting the need for early screening and awareness. He stated that ending Thalassemia is not just a medical goal, but a moral imperative, and that it requires a collective effort from medical professionals, policymakers, NGOs, and the community to tackle the issue at its roots.
The mission, dubbed “Mission 2035,” aims to create a healthier future for generations to come by promoting early screening, genetic counselling, improving access to treatment, and advocating for policy-level reforms to prevent new cases. Jackie Shroff has been an active advocate for healthcare and environmental causes, and his involvement in this initiative is a testament to his commitment to creating a healthier tomorrow.
Through this initiative, Jackie Shroff hopes to spread awareness about Thalassemia and the importance of prevention. He believes that prevention begins with awareness, and that by working together, it is possible to eliminate Thalassemia from India by 2035. The #RedRuntoEndThalassemia event is just the beginning of a larger movement, and Jackie Shroff’s involvement is expected to inspire others to join the cause and work towards a Thalassemia-free India.
Overall, the initiative is a significant step towards addressing the silent crisis of Thalassemia in India, and Jackie Shroff’s involvement is a powerful endorsement of the cause. By supporting this initiative, he hopes to make a positive impact on the lives of thousands of children and families affected by this condition, and to create a healthier future for generations to come.
Alkem Laboratories’ Sarvesh Singh purchases luxurious Mumbai property worth Rs 174 crore, see details
The luxury property market in Mumbai, India’s financial capital, is experiencing a surge in demand, with over Rs 800 crore worth of high-end property deals recorded in February and March alone. Affluent individuals, including business leaders and celebrities, are driving this trend. One notable example is Sarvesh Singh, executive director of Alkem Laboratories, who recently acquired a sea-facing duplex in Bandra’s Supreme ArtHouse for Rs 174 crore. The 12,148 square foot property offers breathtaking views of the Arabian Sea and is considered one of the most expensive home purchases on the Bandra seafront.
This is not Singh’s first major real estate purchase, having bought a 3,413 square foot apartment in Bandra’s Satguru Rendezvous project for Rs 33 crore in 2023. Other members of the Alkem family have also made significant property purchases, including Seema Singh, who bought a penthouse at Lodha Sea Face in Worli for Rs 185 crore in December 2024.
Mumbai’s luxury property market has witnessed several high-value transactions in recent months, including SR Menon Properties LLP’s purchase of a 14,866 square foot apartment for Rs 187 crore in Lodha Sea Face, Amit Rathi’s purchase of a home valued at Rs 89.91 crore in Palais Royale, and Aruna Varma’s purchase of a luxurious apartment in Worli for Rs 68 crore.
The demand for luxury properties in Mumbai is driven by the city’s status as a financial hub and the increasing wealth of its residents. Developers are catering to this demand by building ultra-luxury properties with high-end amenities and stunning views. Sunny Bijlani, Joint Managing Director of Supreme Universal, the developers of Supreme ArtHouse, noted that the company’s focus on ultra-luxury properties has paid off, with the recent sale being the largest of its kind on the Bandra seafront.
Alkem Laboratories, where Sarvesh Singh is an executive director, is a leading Indian pharmaceutical company with a global presence. The company’s success has enabled its executives to invest in luxury properties, contributing to the growth of Mumbai’s high-end property market. Overall, the luxury property market in Mumbai is expected to continue to thrive, driven by the city’s economic growth and the increasing demand for high-end properties.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.